ADMA Biologics Future Growth
Future criteria checks 4/6
ADMA Biologics is forecast to grow earnings and revenue by 26% and 14.8% per annum respectively while EPS is expected to grow by 25.2% per annum.
Key information
26.0%
Earnings growth rate
25.2%
EPS growth rate
Biotechs earnings growth | 29.6% |
Revenue growth rate | 14.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 12 Aug 2024 |
Recent future growth updates
Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02ADMA Biologics: Turning A Corner
Nov 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 529 | 174 | 175 | 189 | 3 |
12/31/2025 | 458 | 157 | 119 | 153 | 4 |
12/31/2024 | 406 | 115 | 58 | 104 | 4 |
6/30/2024 | 330 | 35 | 66 | 73 | N/A |
3/31/2024 | 283 | -4 | 16 | 21 | N/A |
12/31/2023 | 258 | -28 | 4 | 9 | N/A |
9/30/2023 | 234 | -23 | -23 | -16 | N/A |
6/30/2023 | 208 | -40 | -51 | -41 | N/A |
3/31/2023 | 182 | -48 | -61 | -48 | N/A |
12/31/2022 | 154 | -66 | -73 | -60 | N/A |
9/30/2022 | 130 | -70 | -99 | -86 | N/A |
6/30/2022 | 110 | -73 | -99 | -86 | N/A |
3/31/2022 | 94 | -78 | -119 | -105 | N/A |
12/31/2021 | 81 | -72 | -126 | -112 | N/A |
9/30/2021 | 69 | -74 | -125 | -111 | N/A |
6/30/2021 | 58 | -74 | -135 | -122 | N/A |
3/31/2021 | 48 | -75 | -124 | -111 | N/A |
12/31/2020 | 42 | -76 | -115 | -102 | N/A |
9/30/2020 | 40 | -67 | -100 | -89 | N/A |
6/30/2020 | 37 | -61 | -99 | -89 | N/A |
3/31/2020 | 36 | -54 | -92 | -87 | N/A |
12/31/2019 | 29 | -48 | -80 | -76 | N/A |
9/30/2019 | 21 | -56 | -78 | -75 | N/A |
6/30/2019 | 18 | -59 | -66 | -64 | N/A |
3/31/2019 | 16 | -61 | -62 | -61 | N/A |
12/31/2018 | 17 | -66 | -65 | -63 | N/A |
9/30/2018 | 18 | -61 | -61 | -57 | N/A |
6/30/2018 | 18 | -61 | -58 | -54 | N/A |
3/31/2018 | 17 | -55 | N/A | -48 | N/A |
12/31/2017 | 16 | -44 | N/A | -37 | N/A |
9/30/2017 | 14 | -35 | N/A | -28 | N/A |
6/30/2017 | 12 | -24 | N/A | -22 | N/A |
3/31/2017 | 11 | -21 | N/A | -18 | N/A |
12/31/2016 | 11 | -20 | N/A | -18 | N/A |
9/30/2016 | 10 | -20 | N/A | -19 | N/A |
6/30/2016 | 9 | -20 | N/A | -17 | N/A |
3/31/2016 | 8 | -19 | N/A | -16 | N/A |
12/31/2015 | 7 | -18 | N/A | -15 | N/A |
9/30/2015 | 6 | -17 | N/A | -14 | N/A |
6/30/2015 | 6 | -15 | N/A | -14 | N/A |
3/31/2015 | 6 | -15 | N/A | -14 | N/A |
12/31/2014 | 6 | -17 | N/A | -15 | N/A |
9/30/2014 | 5 | -18 | N/A | -15 | N/A |
6/30/2014 | 5 | -17 | N/A | -15 | N/A |
3/31/2014 | 4 | -18 | N/A | -13 | N/A |
12/31/2013 | 3 | -16 | N/A | -11 | N/A |
9/30/2013 | 3 | -13 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADMA's forecast earnings growth (26% per year) is above the savings rate (2.5%).
Earnings vs Market: ADMA's earnings (26% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: ADMA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ADMA's revenue (14.8% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: ADMA's revenue (14.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADMA's Return on Equity is forecast to be high in 3 years time